MarketLens
Sign Up

Tarsus Pharmaceuticals: A Commercial Pivot Under New Leadership

4 months ago
SHARE THIS ON:

Tarsus Pharmaceuticals: A Commercial Pivot Under New Leadership

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 weeks ago

My 'Eye' Is On Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is positioned for growth as Xdemvy ramps commercially toward $2B peak sales, while recent IRX-101 and ALK-101 acquisitions diversify the pipeline. IRX-101's clinical data and un...
Stock News•3 weeks ago

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics won FDA approval for its presbyopia eye drop and outlined commercialization plans, with a funding runway extending to 2029, per an investor panel with CEO Dr. George Magrath and CFO Rob ...
Stock News•4 months ago

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Tarsus Pharmaceuticals' Chief Commercial Officer Aziz Mottiwala is departing to become CEO of a public medical device company. Neera Clase, formerly SVP of Market Access, will serve as interim CCO eff...

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Cisco Stock Fell 15.5% Despite Its Strongest Growth in 15 Years. Is the Dividend Safe?

Stock News•2 hours ago

Prediction: This Will Be Nvidia's Stock Price in 2027 After Its Phenomenal Q3 Results

Stock News•2 hours ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important December 1 Deadline in Securities Class Action - GOOGL, GOOG

Stock News•3 hours ago

The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026

Stock News•3 hours ago

The S&P 500 Is Having the Longest Losing Streak Since February 2020